Effect of probiotics, Bifidobacterium bifidum G9-1, on gastrointestinal symptoms in patients with type 2 diabetes mellitus: study protocol for open-label, single-arm, exploratory research trial (Big STAR study)

• Published in: Journal of Clinical Biochemistry and Nutrition Vol. 67; no. 3; pp. 223 - 227
• Main Authors: Hashimoto, Yoshitaka, Nakajima, Hanako, Hata, Shinnosuke, Miyoshi, Tomoki, Hosomi, Yukako, Majima, Saori, Nakanishi, Naoko, Senmaru, Takafumi, Osaka, Takafumi, Okada, Hiroshi, Ushigome, Emi, Hamaguchi, Masahide, Asano, Mai, Yamazaki, Masahiro, Fukui, Michiaki
• Format: Journal Article
• Language: English
• Published: Gifu SOCIETY FOR FREE RADICAL RESEARCH JAPAN 01.11.2020; Japan Science and Technology Agency; the Society for Free Radical Research Japan
• Subjects: Animal models; Antidiabetics; Bifidobacterium bifidum; biguanides; Biomarkers; Body mass index; Body size; Constipation; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diarrhea; gastrointestinal complications; Gastrointestinal symptoms; gut microbiota; Intestinal microflora; Metformin; Microbiota; Probiotics; Protocol; type 2 diabetes

Metformin is associated with risks of gastrointestinal complications in patients with type 2 diabetes. In contrast, probiotic Bifidobacterium bifidum G9-1 (BBG9-1) could improve the symptoms of diarrhea caused by metformin in animal models. Thus, the primary outcome of this study will be the effect...